安旭生物收盘上涨2.12%，滚动市盈率34.94倍，总市值54.56亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anxu Biological, which closed at 42.93 yuan with a PE ratio of 34.94 times, below the industry average of 56.56 times [1][2] - Anxu Biological's total market capitalization is 5.456 billion yuan, ranking 68th in the medical device industry based on PE ratio [1][2] - The company specializes in the research, production, and sales of POCT reagents and instruments, and has received multiple certifications including EU CE, Canadian, and Australian certifications [1] Group 2 - As of March 31, 2025, Anxu Biological had 5,935 shareholders, a decrease of 278 from the previous period, with an average holding value of 352,800 yuan per shareholder [1] - The latest quarterly report for Q1 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]